Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK based NextGen Bioscience has said that it is in collaboration negotiations with SymbioTec, a German company that develops and markets innovative cancer-fighting products.
Subscribe to our email newsletter
The two companies have signed a letter of intent to come to a collaboration agreement and both companies have expressed confidence in forming a mutually beneficial alliance.
Konstantinos Kardiasmenos, CEO of NextGen, said: “SymbioTec’s drug Oncohist is capable of destroying cancer cells. The drug uses an approach fundamentally different from all currently used methods and represents a real potential to replace existing cancer therapies.”